Search

Displaying results 2591 - 2600 of 7503 in total
  1. Drug

    Magnesium silicate

    go.drugbank.com/drugs/DB13249
    ApprovedWithdrawn

    [L2603] Under the FDA, magnesium silicate is determined as a member of the substances generally recognized as safe (GRAS) to be used as an anticaking agent.[L2605]

  2. Drug

    Diloxanide

    go.drugbank.com/drugs/DB08792
    Experimental

    Although it is not currently approved for use in the United States, it was approved by a CDC study in the treatment of 4,371 cases of Entamoeba histolytica from 1977 to 1990.

  3. Drug

    Phosphocreatine

    go.drugbank.com/drugs/DB13191
    InvestigationalNutraceutical

    It is primarily found endogenously in the skeletal muscles of vertebrates where it serves a critical role as a rapidly acting energy buffer for muscle cell actions like contractions via its ability to

    Synonyms: N-(N-phosphonoamido)sarcosine, N-phosphocreatine
  4. Drug

    Methylprednisolone

    go.drugbank.com/drugs/DB00959
    ApprovedInvestigationalVet approved

    [A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957.

    Mixtures: Neo-medrol, NEO-MEDROL ACNE LOTION
  5. Drug

    Muromonab

    go.drugbank.com/drugs/DB00075
    ApprovedInvestigationalWithdrawn

    Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. … More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method.

  6. Drug

    Iproniazid

    go.drugbank.com/drugs/DB04818
    ApprovedWithdrawn

    Withdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.

    Categories: Monoamine Oxidase Inhibitors, Non-Selective, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  7. Drug

    Valbenazine

    go.drugbank.com/drugs/DB11915
    ApprovedInvestigational

    [A261125] On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively. … [A261165] On April 2017, valbenazine was approved by the FDA under the brand name INGREZZA as the first and only approved treatment for adults with Tardive Dyskinesia (TD).

  8. Drug

    Ibrexafungerp

    go.drugbank.com/drugs/DB12471
    Approved

    [A235384,A235389] Similar to echinocandins, ibrexafungerp targets the fungal β-1,3-glucan synthase, which is not present in humans, limiting the chance of renal or hepatic toxicity. … [A235384,L34349] It was developed out of a need to treat fungal infections that may have become resistant to echinocandins or azole antifungals.

  9. Drug

    Dexamethasone acetate

    go.drugbank.com/drugs/DB14649
    ApprovedInvestigationalVet approved

    [A188724] Dexamethasone acetate has largely been replaced by [dexamethasone] phosphate and continues to be administered for a large variety of inflammatory conditions. … In a June 16 2020 press release highlighting early results of a clinical trial, Randomized Evaluation of COVID-19 Therapy (RECOVERY), it was reported that dexamethasone reduced COVID-19 deaths by approximately

    Mixtures: BAYCUTEN® N CREMA, BAYCUTEN® N CREMA
  10. Drug

    Letermovir

    go.drugbank.com/drugs/DB12070
    ApprovedInvestigational

    Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients.